Table 2 Worst toxicity grade on allocated treatment – nonhaematological toxicities

From: Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

 

wTCFa/X N=39 (%)

wTCF/X+panitumumab N=37(%)

Toxicity

Any grade

Grade 3

Any grade

Grade 3

Infections with normal neutrophils

13 (33.3)

7 (17.9)

23 (62.1)

9 (24.3)

Infections with abnormal (low) neutrophils

2 (5.2)

1 (2.6)

2 (5.4)

0 (0)

Febrile neutropenia

4 (10.3)

4 (10.3)

2 (5.4)

2 (5.4)

Anorexia

25 (64.1)

4 (10.3)

28 (59.4)

9 (24.3)

Nausea

30 (76.8)

7 (17.9)

33 (70.2)

11 (29.7)

Vomiting

22 (56.4)

6 (15.4)

45 (62.1)

6 (16.2)

Diarrhoea

26 (66.7)

6 (15.4)

31 (83.7)

9 (24.3)

Dysphagia

6 (28.2)

2 (5.1)

17 (45.9)

4 (10.8)

Stomatitis

18 (46.2)

1 (2.6)

22 (59.4)

2 (5.4)

Hair loss/alopecia

28 (71.8)

0 (0.0)

23 (62.1)

0 (0.0)

Rash: acne/acneiform

11 (28.2)

0 (0.0)

35 (94.5)

3 (8.1)

Rash: hand-foot skin reaction

24 (61.5)

4 (10.3)

24 (64.8)

2 (5.4)

Nail changes

17 (43.6)

0 (0.0)

10 (27.0)

0 (0.0)

Neuropathy – motor

1 (2.6)

0 (0.0)

1 (2.7)

1 (2.7)

Neuropathy – sensory

20 (41.0)

0 (0.0)

14 (37.4)

0 (0.0)

Allergic reaction/ hypersensitivity

7 (18.0)

1 (2.6)

7 (18.9)

1 (2.7)

Fatigue

36 (92.3)

7 (17.9)

34 (91.8)

11 (29.7)

Watery eyes

11 (28.2)

1 (2.6)

8 (21.7)

1 (2.7)

Hearing impairment

1 (2.6)

0 (0.0)

3 (8.1)

1 (2.7)

Pain: headache

5 (12.9)

0 (0.0)

5 (13.5)

1 (2.7)

Other toxicity

38 (97.4)

23 (58.9)

36 (97.2)

36 (59.4)

  1. aWeekly docetaxel, cisplatin and a fluoropyrimidine (5-fluorouracil or capecitabine).